Geode Capital Management
NMRA icon

Geode Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Geode Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.67M Buy
2,803,916
+196,627
+8% +$272K ﹤0.01% 3209
2026
Q2 		$4.43M Buy
2,607,289
+1,520,424
+140% +$2.89M ﹤0.01% 2977
2026
Q1 		$2.12M Buy
1,086,865
+83,119
+8% +$215K ﹤0.01% 3094
2025
Q4 		$1.8M Buy
1,003,746
+34,818
+4% +$76.2K ﹤0.01% 3205
2025
Q3 		$1.76M Buy
968,928
+52,113
+6% +$84.2K ﹤0.01% 3219
2025
Q2 		$673K Sell
916,815
-1,059,487
-54% -$803K ﹤0.01% 3463
2025
Q1 		$1.98M Buy
1,976,302
+6,022
+0.3% +$10.3K ﹤0.01% 3033
2024
Q4 		$20.9M Sell
1,970,280
-9,567
-0.5% -$115K ﹤0.01% 1947
2024
Q3 		$26.2M Buy
1,979,847
+694,385
+54% +$8.1M ﹤0.01% 1835
2024
Q2 		$12.6M Buy
1,285,462
+833,081
+184% +$8.62M ﹤0.01% 2182
2024
Q1 		$6.22M Buy
452,381
+15,504
+4% +$251K ﹤0.01% 2576
2023
Q4 		$7.45M Buy
436,877
+314,691
+258% +$3.86M ﹤0.01% 2492
2023
Q3 		$1.72M Buy
+122,186
New +$1.53M ﹤0.01% 3120

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Wellcome Trust
Wellcome Trust London, United Kingdom $9.16B AUM 11.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Lunate Capital
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $714M AUM 64.22% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
AlphaCore Capital
AlphaCore Capital La Jolla, California $6.24B AUM 19.96% 1-Year Est. Return

Geode Capital Management's NMRA Position: Q3 2026 in Review

Geode Capital Management increased its Neumora Therapeutics (NMRA) stake by 7.5% in Q3 2026, buying an estimated $272K and bringing the position to 2,803,916 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3209.

Geode Capital Management first reported a position in NMRA in Q3 2023 and has held it in 13 quarters since. The position peaked at $26.2M in Q3 2024. 63 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • Geode Capital Management held 2,803,916 shares of Neumora Therapeutics worth $1.67M as of Q3 2026.
  • Geode Capital Management bought 196,627 Neumora Therapeutics shares in Q3 2026, an estimated $272K.
  • Neumora Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3209 holding.
  • Geode Capital Management first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • Geode Capital Management's Neumora Therapeutics position peaked at $26.2M in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.